HVEM belongs to the TNF Receptor superfamily of transmembrane proteins and plays a role in the activation of T-cells and other lymphocytes. It is expressed in various cells and tissues including spleen, thymus, lung, macrophages, and T-cells. HVEM activation induces a signaling cascade which results in induction of transcription factors NF-kappaB and AP-1. LIGHT (TNFSF14) and TNF-beta (TNFSF1) function as the ligands for HVEM, which can also bind specifically to herpes simplex virus glycoprotein D. Soluble HVEM can act as a “receptor decoy” resulting in inhibition of the activity of the HVEM ligands, LIGHT and TNF-beta. Recombinant human HVEM-Fc Chimera is a 376 amino acid fusion protein containing an N-terminal domain corresponding to the extracellular region of HVEM and a C-terminal domain corresponding to residues 102 to 330 of human IgG1.

Catalog #:

003-HVEMFc

Source:

High-5 (BTI-Tn-5B1-4) Insect Cells

Stability:

The lyophilized protein is stable for a few weeks at room temperature, but best stored at -200C.
Reconstituted HVEM-Fc should be stored in working aliquots at -200C.

Purity:

Greater than 98% by SDS-PAGE and HPLC analyses.

Endotoxin Level:

Endotoxin level is less than 0.1 ng per μg (1EU/μg).

Biological Activity:

Determined by its ability to neutralize 0.25 ng/ml of hTNFß induced cytotoxicity on murine L929 cells. The expected ED50 for this effect is 1.3-1.9 μg/ml of HVEM-Fc.